Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Investigations – page 6

  • 79 clinical trials
  • 29 recruiting
  • 93 conditions
  • 21 countries

Conditions in this area

93 conditions with trials, the busiest first

Drug level12Human epidermal growth factor receptor negative8Fallopian tube cancer6Peritoneal cancer index6Breast cancer5Hormone receptor positive breast cancer5Allergy test4Allergy test positive3BRAF V600E mutation positive3Breast cancer female3Breast cancer metastatic3Hormone receptor positive HER2 negative breast cancer3Magnetic resonance imaging3Ovarian cancer recurrent3Colonoscopy2Cortisol abnormal2Hepatitis B e antigen negative2Hepatitis B virus test2Hypersensitivity2Infertility2Infertility female2Infertility tests normal2Non-small cell lung cancer stage IV2Ovarian cancer2+69

Clinical trials in Investigations

79 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

79 clinical trials

Breast cancer+4

Not recruiting

Study Comparing Ribociclib and Endocrine Therapy to Chemotherapy for Patients with Intermediate-Risk HR+/HER2- Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ribociclib
  • Sponsor:WSG Women's Cancer Study Group GmbH

Allergy test

Not recruiting

Study on Quercus ilex and Quercus robur Allergen Extracts for Patients with Oak Pollen Allergy

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Sodium Chloride
  • Sponsor:Inmunotek S.L.

Non-small cell lung cancer stage IV+1

Not recruiting

Study of Encorafenib and Binimetinib for Patients with BRAFV600E-Mutant Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Binimetinib
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Hepatitis B e antigen negative

Not recruiting

Study on the Effectiveness of Human Hepatitis B Immunoglobulin for Patients with Chronic Hepatitis B

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Human Hepatitis B Immunoglobulin
  • Sponsor:Medizinische Hochschule Hannover

Allergy test

Not recruiting

Study on Allergy to Phleum pratense and Dactylis glomerata: Testing Reactions to Phleum pratense and Dactylis glomerata Pollen Extracts in Patients with Allergies

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Sodium Chloride
  • Sponsor:Inmunotek S.L.

Fallopian tube cancer+2

Not recruiting

Study on Niraparib and Dostarlimab for Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Not Suitable for Platinum Treatment

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Fallopian tube cancer+2

Not recruiting

Study of Pembrolizumab and Chemotherapy for Patients with Recurrent Platinum-Sensitive Low-Grade Serous Ovarian Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Nord Ostdeutsche Gesellschaft Fuer Gynaekologische Onkologie e.V.

Non-small cell lung cancer stage IV+2

Not recruiting

Study comparing brigatinib alone versus brigatinib with carboplatin and pemetrexed combination as first treatment for patients with advanced ALK-positive lung cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Brigatinib
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Oesophagogastroscopy

Not recruiting

Study on the Effect of Lidocaine and Propofol on Sedation Levels During Gastroscopy in Adults

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Propofol
  • Sponsor:Hopital Erasme

Acute myeloid leukaemia+2

Not recruiting

Study on the Safety and Effectiveness of Quizartinib for Children and Young Adults with Acute Myeloid Leukemia (AML)

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Quizartinib Dihydrochloride
  • Sponsor:Daiichi Sankyo Inc.

Leukaemia+1

Not recruiting

Study of dasatinib treatment in children and adolescents with Philadelphia chromosome-positive leukemia who cannot take imatinib or for whom imatinib is not effective

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Dasatinib
  • Sponsor:Bristol Myers Squibb International Corporation

Magnetic resonance imaging+1

Not recruiting

Study Comparing Gadoquatrane with Gadoteric Acid, Gadobutrol, and Gadoteridol for MRI in Adults with Brain or Spinal Cord Issues

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Gadobutrol
  • Sponsor:Bayer AG

Substances studied in this area

The therapies tested most often in Investigations trials.

Sodium Chloride11 clinical trialsPaclitaxel6 clinical trialsHistamine Dihydrochloride5 clinical trialsPembrolizumab4 clinical trialsAbemaciclib3 clinical trialsCapecitabine3 clinical trialsCarboplatin3 clinical trialsDoxorubicin Hydrochloride3 clinical trialsGadobutrol3 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.